Stockscreener 앱 받기
0.111
17.78%
-0.024
시간 외 거래:
.10
-0.011
-9.91%
전일 마감가:
$0.135
열려 있는:
$0.115
하루 거래량:
58.58M
Relative Volume:
1.87
시가총액:
$3.32M
수익:
$4.02M
순이익/손실:
$-4.73M
주가수익비율:
-0.0264
EPS:
-4.21
순현금흐름:
$-5.85M
1주 성능:
+46.05%
1개월 성능:
+7.98%
6개월 성능:
-68.29%
1년 성능:
-92.34%
1일 변동 폭
$0.1027
$0.1248
1주일 범위
$0.0542
$0.23
52주 변동 폭
$0.0542
$1.5195
Petros Pharmaceuticals Inc Stock (PTPI) Company Profile
명칭
Petros Pharmaceuticals Inc
전화
973-242-0005
주소
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK
PTPI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PTPI
Petros Pharmaceuticals Inc
|
0.111 | 3.32M | 4.02M | -4.73M | -5.85M | -4.21 |
|
ZTS
Zoetis Inc
|
165.02 | 73.07B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.14 | 47.43B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.12 | 45.72B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.49 | 17.75B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.75 | 14.03B | 612.78M | -86.37M | -62.91M | -0.87 |
Petros Pharmaceuticals Inc 주식(PTPI)의 최신 뉴스
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Is Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) the Best AI Stock to Invest in According to Reddit? - Yahoo Finance
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Why GameStop Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - Benzinga India
Is Apellis Pharmaceuticals, Inc. (APLS) a Promising Biotech Stock According to Wall Street Analysts - Yahoo Finance
Petro-Victory Energy Corp Announces Extension to US $1,700,000 Note - Yahoo Finance
Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) The Best Extremely Profitable Stocks to Buy According to Analyst? - Yahoo Finance
CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme - Yahoo Finance
Innovations In Medical Technology And Materials Drive Advancements In Erectile Dysfunction Treatments: Key ... - WhaTech
EXCLUSIVE: MIRA Pharmaceuticals Signs To Acquire SKNY Pharmaceuticals, Expand Pipeline Into Weight Loss And Smoking Cessation Drug - Yahoo Finance
Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Petros Pharmaceuticals enters collaboration with big data, analytics firm - MSN
Petros Pharmaceuticals enhances Rx-to-OTC switch technology By Investing.com - Investing.com South Africa
Petros Pharmaceuticals enhances Rx-to-OTC switch technology - Investing.com
Petros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple Indications - ACCESS Newswire
Petros Pharmaceuticals Targets $38B Self-Care Market with Game-Changing AI Drug Platform - StockTitan
PTPI stock plunges to 52-week low of $0.07 amid market challenges By Investing.com - Investing.com South Africa
PTPI stock plunges to 52-week low of $0.07 amid market challenges - Investing.com Australia
Nvidia GTC 2025: What to expect from Nvidia's biggest event of the year - Yahoo Finance
PTPI’s price-to-free cash flow ratio: How it affects investment decisions - US Post News
Regeneron Pharmaceuticals, Inc. (REGN): Hedge Funds Are Bullish On This Oversold Blue Chip Stock Now - Yahoo Finance
TCBP Announces Non-Binding Letter of Intent to Acquire Commercial Stage Ophthalmic Pharmaceutical Company - Yahoo Finance
Entrada Therapeutics, Inc. Just Beat EPS By 55%: Here's What Analysts Think Will Happen Next - Yahoo Finance
Internationally Published, Head-to-Head Data From India of Petros Pharmaceuticals' STENDRA(R) (Avanafil) Tablets Reported Improvement in Erectile Function Compared to Sildenafil and Baseline After 12 Weeks of Therapy - ACCESS Newswire
Pharma Stock Roundup: LLY Ups U.S. Manufacturing Investments & More - Yahoo Finance
Petros Pharmaceuticals Reports Record Revenue and Gross Profit During Second Quarter 2022 - ACCESS Newswire
New FDA-Approved Labeling for Petros Pharmaceuticals’ STENDRA (avanafil) Now Includes Efficacy Data Regarding Use in Men Who Have Undergone Radical Prostatectomy - ACCESS Newswire
Petros Pharmaceuticals stock hits 52-week low at $0.1 By Investing.com - Investing.com South Africa
Petros Pharmaceuticals stock hits 52-week low at $0.1 - Investing.com
Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - Yahoo Finance
Artificial Intelligence (AI) News Live Feed - StockTitan
Petros reports success in AI-assisted Rx-to-OTC study - Investing.com India
Petros reports success in AI-assisted Rx-to-OTC study By Investing.com - Investing.com South Africa
Petros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal Study - ACCESS Newswire
Can Petros Pharmaceuticals' AI-Powered Platform Revolutionize the $38B Self-Care Market? - StockTitan
BioCryst Pharmaceuticals Inc (BCRX) Q4 2024 Earnings Call Highlights: Strong ORLADEYO Revenue ... - Yahoo Finance
Recursion Pharmaceuticals, Inc. (RXRX): The Best Performing Pharma Stock So Far in 2025? - Yahoo Finance
PTPI Page Not Found - Benzinga
Why Viking Therapeutics Inc. (VKTX) Surged On Friday? - Yahoo Finance
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 27, 2025 - Yahoo Finance
Petros Pharmaceuticals announces pricing of $9.6 million public offering - MSN
Form 424B4 Petros Pharmaceuticals, - StreetInsider.com
Ionis Pharmaceuticals Inc (IONS) Q4 2024 Earnings Call Highlights: Surpassing Revenue ... - Yahoo Finance
PTPI stock plunges to 52-week low of $0.15 amid market challenges - Investing.com India
Crude Oil Gains 1.5%; Fluor Shares Plunge Following Downbeat Earnings - Benzinga
Watsco, Septerna, Nike - TradingView
Petros Pharmaceuticals Prices $9.6 Million Public Offering of Shares, Warrants -February 18, 2025 at 09:52 am EST - Marketscreener.com
US Stocks Mixed; NY State Business Activity Rises In February - Benzinga India
Petros Pharmaceuticals sets public offering at $0.24 per share - Investing.com
Petros Pharmaceuticals Inc (PTPI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.46%
0.47%
자본화:
|
볼륨(24시간):